Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

Elisa A. Rozeman; Esmée P. Hoefsmit; Irene L. M. Reijers; Robyn P.M. Saw; Judith M. Versluis; Oscar Krijgsman; Petros Dimitriadis; Karolina Sikorska; Bart A. van de Wiel; Hanna Eriksson; Maria Gonzalez; A. Torres Acosta; Lindsay G. Grijpink-Ongering; Kerwin F. Shannon; John B.A.G. Haanen; Jonathan R. Stretch; Sydney Ch’ng; Omgo E. Nieweg; Henk Mallo; S. Adriaansz; Ron Kerkhoven; Sten Cornelissen; Annegien Broeks; W. Martin C. Klop; Charlotte L. Zuur; Winan J. van Houdt; Daniel S. Peeper; Alexander C.J. van Akkooi; Richard A Scolyer; Ton N. Schumacher; Alexander M. Menzies; Georgina V. Long; Christian U. Blank

doi:10.1038/s41591-020-01211-7

Related publications

Article2022

Survival update of neoadjuvant ipilimumab + nivolumab in macroscopic stage III melanoma: The OpACIN and OpACIN-neo trials.

Judith M. Versluis, Karolina Sikorska, Elisa A. Rozeman, Alexander M. Menzies, Hanna Eriksson, W. Martin C. Klop, Robyn P.M. Saw, Bart A. van de Wiel, Richard A Scolyer, Johannes V. van Thienen, Henk Mallo, Maria Gonzalez, Alex Torres Acosta, Lindsay G. Grijpink-Ongering, Anja van der Wal, John B.A.G. Haanen, Alexander Christopher Jonathan Van Akkooi, Georgina V. Long, Christian U. Blank

Article2023

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials

Judith M. Versluis, Alexander M. Menzies, Karolina Sikorska, Elisa A. Rozeman, Robyn P.M. Saw, Winan J. van Houdt, Hanna Eriksson, W. Martin C. Klop, Sydney Ch’ng, Johannes V. van Thienen, Henk Mallo, Maria Gonzalez, A. Torres Acosta, Lindsay G. Grijpink-Ongering, A. van der Wal, Annemarie Bruining, Bart A. van de Wiel, Richard A Scolyer, John B.A.G. Haanen, Ton N. Schumacher, Alexander C.J. van Akkooi, Georgina V. Long,

Article2024

Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo

Irene L M Reijers, Alexander M Menzies, Marta Lopez-Yurda, Judith M. Versluis, Elisa A. Rozeman, Robyn P.M. Saw, Winan J. van Houdt, Ellen Kapiteijn, Astrid A M van der Veldt, Karijn P.M. Suijkerbuijk, Hanna Eriksson, Geke A.P. Hospers, W. Martin C. Klop, Alejandro Torres Acosta, L. Grijpink-Ongering, Maria Gonzalez, Anja van der Wal, Abrahim Al‐Mamgani, Andrew J. Spillane, Richard A Scolyer,

Article2020

L3 Update of the OpACIN and OpACIN-neo trials: 36-months and 24-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients

Judith M. Versluis, E.A. Rozeman, AM Menzies, ILM Reijers, Oscar Krijgsman, EP Hoefsmit, BA van de Wiel, Karolina Sikorska, Carolien Bierman, Petros Dimitriadis, Maria Gonzalez, Annegien Broeks, RM Kerkhoven, Andrew J. Spillane, J.B.A.G. Haanen, W. van Houdt, Rpm Saw, Hanna Eriksson, Alexander C.J. van Akkooi, Richard A Scolyer, TN Schumacher,

Article2020

Abstract 3412: 36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients - update of the OpACIN and OpACIN-neo trials

Christian U. Blank, Judith M. Versluis, Elisa A. Rozeman, Alexander M. Menzies, Irene L. M. Reijers, Oscar Krijgsman, Esmée P. Hoefsmit, Bart A. van de Wiel, Karolina Sikorska, Carolien Bierman, Petros Dimitriadis, Maria Gonzalez, Annegien Broeks, Ron Kerkhoven, Andrew J. Spillane, John B.A.G. Haanen, Winan J. van Houdt, Robyn P.M. Saw, Hanna Eriksson, Alexander C.J. van Akkooi, ,